The administration will not endorse the widespread use of march-in rights, and is not expected to take action against any individual medicines, said the people familiar with the matter, who were granted anonymity to discuss internal decision making.

Important bit from that, lest anyone think they’re actually going to do something.

I would be delighted if they did, but I would also be very surprised if they actually assert these rights on medicines developed with public funds, which is what they should do - just all of the medicines developed with public funds, patents seized, end of story.